Nal Pharmaceutical Group Limited
Pharmaceuticals, Shung Wan, New Jersey, 08852, United States, 51-200 Employees
Who is NAL PHARMACEUTICAL GROUP LIMITED
NAL Pharma is a specialty drug developer that develops novel dosage forms and proprietary drug delivery systems based on the Companys captive Bio-D3, Bio-FX, Bio-CR, Bio-NN, and Bio-MM Dr...
Read More
-
Headquarters: Shung Wan, New Jersey, 08852, United States
-
Date Founded: 2006
-
Employees: 51-200
-
Revenue: $5 Million to $10 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 2834
|
NAICS Code: 424210 |
Show More
Does something look wrong? Fix it. | View contact records from NAL PHARMACEUTICAL GROUP LIMITED
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding NAL Pharmaceutical Group Limited
Answer: NAL Pharmaceutical Group Limited's headquarters are located at Shung Wan, New Jersey, 08852, United States
Answer: NAL Pharmaceutical Group Limited's official website is https://nalpharma.com
Answer: NAL Pharmaceutical Group Limited's revenue is $5 Million to $10 Million
Answer: NAL Pharmaceutical Group Limited's SIC: 2834
Answer: NAL Pharmaceutical Group Limited's NAICS: 424210
Answer: NAL Pharmaceutical Group Limited has 51-200 employees
Answer: NAL Pharmaceutical Group Limited is in Pharmaceuticals
Answer: NAL Pharmaceutical Group Limited contact info: Phone number: Website: https://nalpharma.com
Answer: NAL Pharma is a specialty drug developer that develops novel dosage forms and proprietary drug delivery systems based on the Companys captive Bio-D3, Bio-FX, Bio-CR, Bio-NN, and Bio-MM Drug Delivery System (DDS) technologies. Headquartered in Hong Kong and with operation in the United States, NAL is developing non-infringing, proprietary and improved drug delivery systems that exhibit enhanced patient-compliance, safety, and/or efficacy compared with existing pharmaceutical products, and is also developing specially designed delivery systems to improve conventional dosage forms of new drugs undergoing Phase 2 clinical development that show significant first-pass metabolism side effects, poor solubility, and poor bioavailability. As the US operation of NAL, Galaxy Bio, Inc. ("GBI") has established a captive R&D Laboratory in Princeton, New Jersey, USA for the development of afore-mentioned NAL's innovative and proprietary DDS products. Combining established product formulation and manufacturing development expertise, NAL has developed a number of non-infringing, proprietary and improved therapeutic products that incorporate patent-expiring drugs. NAL is working with major consumer healthcare companies to extend the life cycle of patent expiring drugs for the Rx-to-OTC switch. NAL is also working with major pharmaceutical companies to improve the formulations of their NCE drugs under development, in an effort to develop the most effective delivery systems based on NALs proprietary DDS Technologies.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month